Starlight Cardiovascular, a San Diego, CA-based preclinical stage medical technology company, raised $9.48M in Series A funding.
The round, which included conversion of previously-issued notes, was led by Bird B.
The company intends to use the funds to progress development of its portfolio of pediatric interventional cardiology devices.
Led by CEO Beverly Tang and Co-founder Dr. Pedro del Nido, Chairman of Cardiac Surgery at Boston Children’s Hospital, Starlight Cardiovascular is a preclinical stage medical technology company developing a portfolio of devices to address pediatric Congenital Heart Disease. Its first product, a Ductus Arteriosus Stent, replaces a life-saving open chest surgery with a microcatheter-based procedure performed through a small incision in the skin.